Alan’s €5 Billion Valuation: A Sign of Health Tech Resilience?
Despite a challenging environment for European startups, French health insurance company Alan has secured a €5 billion (approximately $5.83 billion) valuation. This achievement, up from $4.5 billion in 2024, signals potential resilience within the health tech sector and offers insights into evolving investor priorities.
The European Unicorn Landscape
Recent data suggests a downturn for European unicorns, with approximately 30% potentially losing their billion-dollar status. Alan’s success stands in stark contrast, demonstrating that strong fundamentals and a clear path to growth can still attract significant investment. This divergence highlights a growing selectivity among investors, favoring companies demonstrating profitability or a clear route to it.
Alan’s Growth Trajectory
Founded in 2016, Alan now serves one million employees, freelancers, and retirees. The company’s app provides a comprehensive suite of services, including reimbursement management, doctor access, and health habit tracking. A recent €100 million ($116 million) funding round, led by Index Ventures with participation from Greenoaks, Kaaf, SH, Belfius, Shopify founder Tobi Lütke, and Antoine Griezmann, fuels its expansion plans.
Expanding Market Reach and Revenue Growth
Alan’s growth isn’t limited to its home market. The company has secured contracts to provide health insurance to 135,000 French civil servants and has expanded into Belgium, Spain, and Canada. In 2025, Alan reported €785 million ($915 million) in annual recurring revenue (ARR), a 53% increase from 2024. The company is approaching operational break-even, having halved its losses as a percentage of revenue over the past year, despite previous net losses of $61 million in 2023 and $56 million in 2024.
The Role of AI and Strategic Partnerships
Alan’s CEO, Jean-Charles Samuelian-Werve, as well holds a position at Mistral AI, a French AI company. This connection underscores Alan’s commitment to leveraging artificial intelligence to enhance its services. The company intends to “invest ambitiously, particularly in [tech] and [AI].” Strategic partnerships, such as the ongoing collaboration with Belfius, are also crucial to Alan’s continued success.
Future Focus: ARR Growth Over Immediate Profitability
While nearing operational break-even, Alan is prioritizing ARR growth, aiming for $1.16 billion in 2026. This strategy suggests a willingness to forgo immediate profitability in favor of long-term market dominance and continued innovation. Investors appear to support this approach, recognizing the potential for substantial returns in the rapidly evolving health tech landscape.
Pro Tip
For startups seeking funding in a challenging economic climate, Alan’s success demonstrates the importance of demonstrating strong revenue growth, a clear path to profitability, and a commitment to innovation.
FAQ
Q: What is Alan’s current valuation?
A: €5 billion (approximately $5.83 billion).
Q: Where does Alan currently operate?
A: France, Belgium, Spain, and Canada.
Q: What is Alan’s annual recurring revenue (ARR)?
A: €785 million (approximately $915 million) as of 2025.
Q: Is Alan profitable?
A: Alan is approaching operational break-even and has significantly reduced its losses.
Q: Who are some of Alan’s investors?
A: Index Ventures, Greenoaks, Kaaf, SH, Belfius, Tobi Lütke, and Antoine Griezmann.
Did you know? Alan was the first new independent insurance company to receive a license in France since the 1980s.
Want to learn more about the future of health tech? Explore our other articles or subscribe to our newsletter for the latest insights.
